Full Press Release Details
Pharmaceuticals was Chosen to Present Two Abstracts at
Scientific Sessions of the American Diabetes Association in
FL, June 25-29, 2010
IL - June 15, 2010 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)
(http://www.oramed.com), a developer of alternative drug delivery
systems, announced today that results of two of its clinical
trials will be presented by Chief Scientific Officer Dr. Miriam Kidron, at the
forthcoming 70th Annual
Scientific Sessions of the American Diabetes Association, to be held in Orlando,
Florida. The first abstract, entitled "Oral Insulin: Type I Diabetes
(T1DM) Patient Response Upon Preprandial Administration" examines exposure of
Type 1 diabetes patients to Oramed's oral insulin. The second
abstract, entitled "A Single-Blind, Two-period Study to Assess the Safety and
Pharmacodynamics of an Orally Delivered GLP-1 Analog (Exenatide) in Healthy
Subjects" details a first-in-human study with Oramed's oral GLP-1
posters will be presented on June 28, 2010 at 12:00 PM - 2:00 PM in the Poster
Hall. The posters will also be printed in the Scientific Sessions
Abstract book which is the June 2010 supplement for the Journal Diabetes. The posters will be
displayed throughout the conference for viewing in the Poster Hall.
poster entitled "Oral Insulin: Type I Diabetes (T1DM) Patient Response Upon
Preprandial Administration" will be featured in a guided tour in the Poster
Hall. The tour title is "Innovations in Novel Insulin Preparations" and is
scheduled for Monday June 28 at 12:00-1:00 PM.
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product,
an orally ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research
performed by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit http://www.oramed.com.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts:
Pharmaceuticals Inc.